Avanir Pharmaceuticals (NASDAQ:AVNR) got hit hard when their drug candidate AVP-923 failed to do better than a placebo in a key mid-stage multiple sclerosis trial, disappointing investors and knocking shares down more than 50%. The drug is already being sold as Nuedexta and that has been a success. Nuedexta double-digit sequential revenue growth shouldn’t be ignored — particularly if growth continues again this quarter. Since other biotechs are being acquired at up to 10 times sales, an argument can be made that Avanir’s current market cap of $600 million reflects only Nuedexta.Especially if a larger company wants to acquire them. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) stock opened at $4.29 in last session, and closed at $5.00, while the day range of AVNR stock is $4.22-$5.08.The stock showed a positive weekly performance of 16.55%.
OraSure Technologies (NASDAQ:OSUR) was upgraded by equities researchers at Thomson Reuters/Verus from a “hold” rating to a “buy” rating in a research report issued on Monday, AnalystRatings.Net reports. OraSure Technologies, Inc. (NASDAQ:OSUR) stock opened at $7.55, in last session and closed at $8.23, by gained 11.37%.The 52 week range was $3.75-$8.48.Company’s market capitalization is $457.60 million.
Synthetic Biologics Inc. (NYSEMKT:SYN). On Feb. 13 announced that in view of the unusual market activity in the Company’s stock, the NYSE MKT (the “Exchange”) has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity. Synthetic Biologics Inc (NYSEMKT:SYN) stock gained 5.07% and finished the last session at $2.90.The EPS of the stock remained -0.47.Company’s market capitalization is $168.20 million.
TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women’s healthcare company, announced results for the three-month period and full-year ended December 31, 2013 Net revenue increased to $2.9 million compared with $1.2 million for the fourth quarter of 2012;. TherapeuticsMD Inc (NYSEMKT:TXMD) stock opened the session at $7.07, and closed the session at $7.43. The 52 week range of the TXMD stock remained $1.65-$7.45 and the day range was $7.07-$7.45.